Combination chemotherapy in advanced gastrointestinal cancers: Ex vivo sensitivity to gemcitabine and mitomycin C

British Journal of Cancer

Volumn 89, Issue 12, 2003, Pages 2299-2304

  Whitehouse, P A ^a   Mercer, S J ^a   Knight, L A ^a   Di Nicolantonio, F ^a   O'Callaghan, A ^b   Cree, I A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

ATP TCA; Chemotherapy; Colorectal cancer; Gemcitabine; Mitomycin C; Oesophageal cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; MITOMYCIN; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; ESOPHAGUS CARCINOMA; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; HUMANS; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING;

EID: 0842287218     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601403     Document Type: Article

References (51)

1. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282
2. Aung TT, Davis MA, Ensiminger WD, Lawrence TS (2000) Interaction between gemcitabine and mitomycin-C in vitro. Cancer Chemother Pharmacol 45: 38-42
3. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 2335-2340
4. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17(1): 12-18
5. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13(11): 2731-2736
6. Catalano C, Gianesini C, Fabbian F (2002) Erthyropoietin is beneficial in mitomycin-induced haemolytic-uremic syndrome. Nephron 91(2): 324-326
7. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT (2000) Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 11: 235-237
8. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
9. Christman K, Kelson D, Saltz L, Tarassoff PG (1994) Phase I trial of gemcitabine in patients with advanced gastric cancer. Cancer 73: 5-7
10. Cree IA (1998) Luminescence-based cell viability testing. In Bioluminescence Methods and Protocols, Methods in Molecular Biology Vol 102. LaRossa RA (ed) pp 169-177. Clifton, UK: Humana Press
11. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EMM, Subedi AMC, James EA, Dewar JA, Preece PE, Andreotti PE, Bruckner HW (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7: 630-635
12. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE (1999) Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anti-Cancer Drugs 10: 437-444
13. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
14. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicentre randomised trial. Lancet 355: 1041-1047
15. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A (1994) A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616
16. Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63(11-12): 1727-1733
17. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll H-J (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO 512 (abstract)
18. Gundappa RK, Sud K, Kohli HS, Gupta KL, Joshi K, Sakhuja V (2002) Mitomycin-C induced haemolytic uremic syndrome: a case report. Ren Fail 24(3): 373-377
19. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluoro-deoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
20. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Andreotti PE (1993) Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 19: 242-249
21. Hunter EM, Sutherland LA, Cree IA, Subedi AMC, Hartmann D, Andreotti PE (1994) The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anti-Cancer Drugs 5: 171-176
22. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16(5): 1826-1834
23. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomised study of 5-fluouracil and and cisplatin versus 5-fluouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818
24. Klapdor R, Muller C, Seutter R, Bahlo M, Peters W, Fenner C (2000) Improvement of survival by efficacy orientated polychemotherapy of exocrine pancreatic cancer. Anticancer Res 20: 5201-5207
25. Korneck GV, Potter R, Selzer E, Schratter A, Ulrich-Pur H, Rogy M, Kraus G, Scheithauer W (2001) Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 49: 665-671
26. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Poch G, Indefrei D, Mallmann P, Andreotti PE (1997) Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 3: 1527-1533
27. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS (1979) 5-fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44: 42-47
28. Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, Fortunato S, Pedicini T, Borsellino N, Lopez M, Colucci G (2000) 5-flurouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicentre randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 11: 1045-1051
29. Mani S, Kugler JW, Knost JA, Sciortino DF, Gibbons J, Garcia JC, Ansari RH, Schilsky RL, Vokes EE (1998) Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 16: 275-278
30. Markman M (2002) Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 29(1 Suppl 1): 9-10
31. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Simon Toh S, Cree IA, for the Portsmouth Upper GI Cancer Multi-Disciplinary Team (2003) Heterogeneity of chemosensitivity of oesophageal and gastric carcinoma. Anti-Cancer Drugs 14: 397-403
32. Moertel C, Reitemeier R, Hahn R (1968) Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204: 1045-1048
33. Moore DF, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL (1992) Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10: 323-325
34. Moore GE, Bross DJ, Ausman R, Nadler S, Jones R, Slack N, Rimm AA (1968) Effects of mitomycin C (NSC-26980) in 346 patients with advanced cancer. Cancer Chem Rep 52(6): 675-684
35. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1999) Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 79: 1487-1493
36. NICE (2002) Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer - Technology Appraisal Guidance No. 33. National Institute for Clinical Excellence: London
37. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 10(6): 904-911
38. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(4 Suppl 11): 72-79
39. Poch G, Reiffenstein RJ, Kock P, Pancheva SN (1995) Uniform characterization of potentiation in simple and complex situations when agents bind to different molecular sites. Can J Physiol Pharmacol 73: 1574-1581
40. Price T, Cunningham D, Hickish T, Tait D, Norman A, Ross PJ, Middleton G, Ford HE, Sumpter K (1999) Phase III study of mitomycin-C wth protracted venous infusion 5FU or circadian timed infusion 5FU in advanced colorectal cancer. Proc ASCO 1008 (abstract)
41. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomised trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advance esophagogastric cancer. J Clin Oncol 20(8): 1996-2004
42. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
43. Russello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A (1989) Time-dependent interactions between 5-fluorouracil and mitomycin C on a human cancer cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 25: 571-572
44. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
45. Sandler AB, Nemunatis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold Ch, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn KH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122-130
46. Sartorelli AC, Booth BA (1965) The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluourouracil. Cancer Res 25: 1393-1400
47. Spanswick VJ, Cummings J, Ritchie AA, Smyth JF (1998) Pharmacological determinants of the antitumour activity of mitomycin C. Biochem Pharm 56: 1497-1503
48. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M (2002) A multicentre randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PV 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol 13(10): 1568-1575
49. van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Postmus PE, Peters GJ (2000) Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 83(8): 2420-2429
50. van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ (1997) Combination chemotherapy studies with gemcitabine. Semin Oncol 24(2 Suppl 7): S7-17-S7-23
51. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumour chemosensitivity assay (ATP-TCA). Anticancer Drugs 14: 369-375